Member Info for TrickyEFC

Although it's for a completely different medical condition it's worth using it as a guide to the size of the market place.

Solvonis' market

In the US, excessive alcohol use causes an estimated 178,000 deaths annually, making it a leading preventable cause of death. This figure includes deaths related to both acute and chronic effects of alcohol. Specifically, about 119,600 deaths occur among males, and 58,700 among females

Apraglutide market

In 2023, it was estimated that there would be 153,020 new cases of colorectal cancer in the United States, with 106,970 in the colon and 46,050 in the rectum. The American Cancer Society estimates that about 52,900 deaths will occur from colorectal cancer in 2023.

All about the current potential

£1 bill and it's not yet a commercial product.

Apraglutide is not yet commercially available for general use. It is currently in clinical development, primarily for the treatment of short bowel syndrome with intestinal failure (SBS-IF). While Ironwood Pharmaceuticals has initiated a rolling New Drug Application (NDA) submission to the FDA, and has reported positive data from Phase III trials, it is not yet approved for any indication.

Sound familiar like a little bit of history could be repeating itself

VectivBio's valuation was based on its pipeline of therapies for rare diseases, particularly its Phase 3 study drug Apraglutide for short bowel syndrome. Ironwood believes Apraglutide has the potential to generate $1 billion in net sales

VectivBio's valuation was based on its pipeline of therapies for rare diseases, particularly its Phase 3 study drug Apraglutide for short bowel syndrome. Ironwood believes Apraglutide has the potential to generate $1 billion in net sales

Of the 4 companies he is board director and committee chair only one is valued under the billions.

Interestingly vectivBio only recently

VectivBio Inc. was acquired by Ironwood Pharmaceuticals for approximately $1 billion. The acquisition was finalized on June 29, 2023. VectivBio's valuation was based on its pipeline of therapies for rare diseases, particularly its Phase 3 study drug Apraglutide for short bowel syndrome. Ironwood believes Apraglutide has the potential to generate $1 billion in net sales, according to Basel Area Business & Innovation and Ironwood Pharmaceuticals, citing that the addition of apraglutide provides another high-growth potential revenue stream and diversifies Ironwood's portfolio

Long and far ranging tentacles

Stephen Page has worked at Chief Executive and Board level in UK healthcare for over 30 year, most noticeably leading Priory Healthcare, the largest network of mental healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organisations in both public and private sectors including Oxleas NHS Trust in London, Nestor plc and Acorn Care and Education.

As founding CEO of Acorn Care and Education, and supported by Phoenix Equity Partners, Steve built the company via acquisition and organic growth to be a leading national provider of special needs education and foster care. He led the sale to the Ontario Teachers’ Pension Plan in 2010.

Steve has a Business Studies Degree from Sheffield University and an MBA from London Business School

Cut this lil bit. Ned at Awakn.

where he was responsible for the company’s worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time.

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, specializing in commercialization, regional leadership and mergers and acquisitions. Mr. Carter is currently a Board Director and Committee Chair of four US listed BioPharma companies HutchMed PLC, Mallinckrodt Pharmaceuticals, Immatics NV, and VectivBio Inc.

Prior to this, Mr. Carter served as Executive Vice-President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company’s worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time. Before that Paul had senior leadership roles in GSK (and its legacy companies), including head of GSK China and head of Smith Kline Beecham Russia. He has lived and worked extensively in the US, Europe and Asia and continues to be strongly networked and professionally connected to a diverse range of publicly listed and private life science orientated businesses in these territories.

Globally and exclusivity for like think its 8years america 10 for europe

Chas been a fantastic week. stampee it could certainly well be cheap at 500mill.

1.7p per share would value us at approx 140 million.

if it gets past 1p id prob apply for the more kare study :p how ironic

could this hit several pennies in years to come, some of the other posters seem to think so

Some big buys above 18 today will expect the same tomorrow orders taking us up again but will it be more pronounced tomorrow as surely its not just us pis mopping up these shares.

should start seeing bigger moves over the coming days

Current value £13.7 mill.

banging a drum but this needs to triple in value before it hits a reasonable value.

This is without any further updates as it stands with what we know and more importantly the market knows its massively undervalued.

Need for further fundraising

Posted before reading rest of posts. jockey andy in the house.

yes will the 22 arrive by Monday and if it does will we fly to 28

I'd like to say its taken awhile but the race only started last june.

raised at 0.10p before dilution just shy of 50% of shares where held by long termers.

raised at 30% premium 11 months on.

today approx 30% up on the fundraise at 0.13p and pretty much done the 1.5bill volume since the 1.5bill hit on the 22nd of may.

Phase 3 fully funded.

If phase 3 goes as well as phase 2 then SOLVONIS would not have any need for fair fundraising.

If this goes well then you will all be a hell of a lot richer than you are now or less poor for those like me lol

Evening bones I do.

can't believe how quite it was here.

we do have some long time holders like andy and others cant remember names right now, but yer it was tumble weed city.

lovely to see the spot light starting to shine on this Monster in the making.

Still believe we need to do at least 150% fro m here to get to a fair starting price.

daffy and others saying 100mil value so about 2p possible. i just cant believe its currently this cheap.

hopefully we get a david nutt interview this time as he would deliver a better presentation regarding this latest rns as opposed to anthony.

Wonder if any orders on 18s will be printed after close

Mr 1% 😂😂😂😂

Dv last trade was another in and out with 89 quid.

The sky is the limit but pretty quickly we should see the 0.5s

3 bag from this current price is £39 mill which most would conclude is a more rational starting point for this journey

250 mill

Long may it continue